Multiple sclerosis: Basic knowledge and new insights in perioperative management

Journal of Anesthesia

Volumn 28, Issue 2, 2014, Pages 267-278

  Makris, Alexandros ^a   Piperopoulos, Alexandros ^a   Karmaniolou, Iosifina ^b  

^a Department of Anesthesiology Asklepieion Hospital of Voula   (Greece)

^b ROYAL NATIONAL ORTHOPAEDIC HOSPITAL   (United Kingdom)

Author keywords

General anesthesia; Multiple sclerosis; Regional anesthesia

Indexed keywords

BETA INTERFERON; CYCLOPHOSPHAMIDE; FINGOLIMOD; GLATIRAMER; IMMUNOMODULATING AGENT; MITOXANTRONE; NATALIZUMAB;

CLINICAL FEATURE; DISEASE EXACERBATION; ELECTROCONVULSIVE THERAPY; GENERAL ANESTHESIA; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; MEDLINE; MULTIPLE SCLEROSIS; NERVE BLOCK; PATHOGENESIS; PERIOPERATIVE PERIOD; PERIPHERAL NERVE; PREOPERATIVE EVALUATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGIONAL ANESTHESIA; REVIEW; SYSTEMATIC REVIEW; PATHOLOGY; PROCEDURES;

ANESTHESIA, CONDUCTION; ANESTHESIA, GENERAL; HUMANS; MULTIPLE SCLEROSIS; PERIOPERATIVE CARE; PERIOPERATIVE PERIOD;

EID: 84899637954     PISSN: 09138668     EISSN: 14388359     Source Type: Journal    
DOI: 10.1007/s00540-013-1697-2     Document Type: Review

References (130)

1. Charcot JM. Histologie de la sclerose en plaques. Gazette des Hopitaux. 1868;41:554-5.
2. Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372:1502-17.
3. Rosati G. The prevalence of multiple sclerosis in the world: an update. Neurol Sci. 2001;22:117-39. (Pubitemid 33771279)
4. Koch-Henriksen N, Sørensen PS. The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurol. 2010;9:520-32.
5. Confavreux C, Vukusic S. Age at disability milestones in multiple sclerosis. Brain. 2006;129:595-605. (Pubitemid 43278222)
6. Manouchehrinia A, Constantinescu CS. Cost-effectiveness of disease-modifying therapies in multiple sclerosis. Curr Neurol Neurosci Rep. 2012;12:592-600.
7. Tremlett H, Zhao Y, Devonshire V. Natural history comparisons of primary and secondary progressive multiple sclerosis reveals differences and similarities. J Neurol. 2009;256:374-81.
8. Stuke K, Flachenecker P, Zettl UK, Elias WG, Freidel M, Haas J, Pitschnau-Michel D, Schimrigk S, Rieckmann P. Symptomatology of MS: results from the German MS Registry. J Neurol. 2009;256:1932-5.
9. Olek MJ. Epidemiology and clinical features of multiple sclerosis in adults. In: Basow DS, editor. UpToDate. Waltham: UpToDate; 2012.
10. Steens A, Heersema DJ, Maurits NM, Renken RJ, Zijdewind I. Mechanisms underlying muscle fatigue differ between multiple sclerosis patients and controls: a combined electrophysiological and neuroimaging study. Neuroimage. 2012;59:3110-8.
11. Skokou M, Soubasi E, Gourzis P. Depression in multiple sclerosis: a review of assessment and treatment approaches in adult and pediatric populations. ISRN Neurol. 2012;2012:427102.
12. Truini A, Barbanti P, Pozzilli C, Cruccu G. A mechanism-based classification of pain in multiple sclerosis. J Neurol. 2013;260:351-67.
13. Al-Araji AH, Oger J. Reappraisal of Lhermitte's sign in multiple sclerosis. Mult Scler. 2005;11:398-402. (Pubitemid 40984233)
14. Buchter B, Dunkel M, Li J. Multiple sclerosis: a disease of affluence? Neuroepidemiology. 2012;39:51-6.
15. Santiago O, Gutierrez J, Sorlozano A, de Dios Luna J, Villegas E, Fernandez O. Relation between Epstein-Barr virus and multiple sclerosis: analytic study of scientific production. Eur J Clin Microbiol Infect Dis. 2010;29:857-66.
16. Lang HL, Jacobsen H, Ikemizu S, Andersson C, Harlos K, Madsen L, Hjorth P, Sondergaard L, Svejgaard A, Wucherpfennig K, Stuart DI, Bell JI, Jones EY, Fugger L. A functional and structural basis for TCR cross-reactivity in multiple sclerosis. Nat Immunol. 2002;3:940-3. (Pubitemid 35154007)
17. Mikaeloff Y, Caridade G, Tardieu M, Suissa S. Parental smoking at home and the risk of childhood-onset multiple sclerosis in children. Brain. 2007;130:2589-95. (Pubitemid 47511711)
18. Pierrot-Deseilligny C. Clinical implications of a possible role of vitamin D in multiple sclerosis. J Neurol. 2009;256:1468-79.
19. International Multiple Sclerosis Genetics Consortium; Wellcome Trust Case Control Consortium 2. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature (Lond) 2011;476:214-219.
20. Goodin DS. The causal cascade to multiple sclerosis: a model for MS pathogenesis. PLoS ONE. 2009;4:e4565.
21. Hedström AK, Hillert J, Olsson T, Alfredsson L. Exposure to anaesthetic agents does not affect multiple sclerosis risk. Eur J Neurol. 2013;20:735-9.
22. Gandhi R, Laroni A, Weiner HL. Role of the innate immune system in the pathogenesis of multiple sclerosis. J Neuroimmunol. 2009;221:7-14.
23. Loma I, Heyman R. Multiple sclerosis: pathogenesis and treatment. Curr Neuropharmacol. 2011;9:409-16.
24. Flensner G, Ek AC, Söderhamn O, Landtblom AM. Sensitivity to heat in MS patients: a factor strongly influencing symptomology. An explorative survey. BMC Neurol. 2011;11:27.
25. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O'Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69:292-302.
26. Tsang BK, Macdonell R. Multiple sclerosis: diagnosis, management and prognosis. Aust Fam Phys. 2011;40:948-55.
27. Río J, Comabella M, Montalban X. Multiple sclerosis: current treatment algorithms. Curr Opin Neurol. 2011;24:230-7.
28. Sorensen PS, Ross C, Clemmesen KM, Bendtzen K, Frederiksen JL, Jensen K, Kristensen O, Petersen T, Rasmussen S, Ravnborg M, Stenager E, Koch-Henriksen N, Danish Multiple Sclerosis Study Group. Clinical importance of neutralizing antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet. 2003;362:1184-91. (Pubitemid 37255344)
29. Schmied M, Duda PW, Krieger JI, Trollmo C, Hafler DA. In vitro evidence that subcutaneous administration of glatiramer acetate induces hyporesponsive T cells in patients with multiple sclerosis. Clin Immunol. 2003;106:163-74. (Pubitemid 36428988)
30. Harrison DM, Gladstone DE, Hammond E, Cheng J, Jones RJ, Brodsky RA, Kerr D, McArthur JC, Kaplin A. Treatment of relapsing-remitting multiple sclerosis with high-dose cyclophosphamide induction followed by glatiramer acetate maintenance. Mult Scler. 2012;18:202-9.
31. Fazekas F, Lublin FD, Li D, Freedman MS, Hartung HP, Rieckmann P, Sørensen PS, Maas-Enriquez M, Sommerauer B, Hanna K, PRIVIG Study Group, UBC MS/MRI Research Group. Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial. Neurology. 2008;71:265-71.
32. Cortese I, Chaudhry V, So YT, Cantor F, Cornblath DR, Rae-Grant A. Evidence-based guideline update: plasmapheresis in neurologic disorders. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2011;76:294-300.
33. King AM, Menke NB, Katz KD, Pizon AF. 4-Aminopyridine toxicity: a case report and review of the literature. J Med Toxicol. 2012;8:314-21.
34. Le Page E, Leray E, Taurin G, Coustans M, Chaperon J, Morrissey SP, Edan G. Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients. J Neurol Neurosurg Psychiatry. 2008;79:52-6.
35. Kheder A, Nair KP. Spasticity: pathophysiology, evaluation and management. Pract Neurol. 2012;12:289-98.
36. Langford RM, Mares J, Novotna A, Vachova M, Novakova I, Notcutt W, Ratcliffe S. A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis. J Neurol. 2013;260:984-97.
37. Rossi S, editor. Australian medicines handbook. Adelaide: Australian Medicines Handbook; 2011.
38. Tremlett HL, Yoshida EM, Oger J. Liver injury associated with the beta-interferons for MS: a comparison between the three products. Neurology. 2004;62:628-31. (Pubitemid 38252808)
39. Racke M, Lovett-Racke A, Krandikar N. The mechanism of action of glatiramer acetate treatment in multiple sclerosis. Neurology. 2010;74:S25-30.
40. Dahdaleh D, Altmann DM, Malik O, Nicholas RS. Breathlessness, night sweats, and weight loss on natalizumab. Lancet. 2012;380:726-7.
41. Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L, TRANSFORMS Study Group. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362:402-15.
42. Mitchell G. An update on multiple sclerosis therapy. Med Clin N Am. 1993;77:231-49.
43. Wonsiewicz MJ, Melvin S. Neurologic syndromes and disorders with their anesthetic implications. In: Albin MS, editor. Textbook of neuroanesthesia: with neurosurgical and neuroscience perspectives. New York: McGraw-Hill; 1996. p. 421-6.
44. Nicholson G, Burrin JM, Hall GM. Peri-operative steroid supplementation. Anaesthesia. 1998;53:1091-104. (Pubitemid 28505344)
45. Orange JS, Hossny EM, Weiler CR, Ballow M, Berger M, Bonilla FA, Buckley R, Chinen J, El-Gamal Y, Mazer BD, Nelson RP Jr, Patel DD, Secord E, Sorensen RU, Wasserman RL, Cunningham-Rundles C, Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol. 2006;117:S525-53.
46. Shemin D, Briggs D, Greenan M. Complications of therapeutic plasma exchange: a prospective study of 1,727 procedures. J Clin Apher. 2007;22:270-6. (Pubitemid 350013061)
47. Havla JB, Pellkofer HL, Meinl I, Gerdes LA, Hohlfeld R, Kümpfel T. Rebound of disease activity after withdrawal of fingolimod (FTY720) treatment. Arch Neurol. 2012;69:262-4.
48. O'Connor PW, Goodman A, Kappos L, Lublin FD, Miller DH, Polman C, Rudick RA, Aschenbach W, Lucas N. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology. 2011;76:1858-65.
49. Siger M, Durko A, Nicpan A, Konarska M, Grudziecka M, Selmaj K. Discontinuation of interferon beta therapy in multiple sclerosis patients with high pre-treatment disease activity leads to prompt return to previous disease activity. J Neurol Sci. 2011;303:50-2.
50. Mutluay FK, Gurses HN, Saip S. Effects of multiple sclerosis on respiratory functions. Clin Rehabil. 2005;19:426-32. (Pubitemid 40716421)
51. Altintas A, Demir T, Ikitimur HD, Yildirim N. Pulmonary function in multiple sclerosis without any respiratory complaints. Clin Neurol Neurosurg. 2007;109:242-6.
52. Grasso MG, Lubich S, Guidi L, Rinnenburger D, Paolucci S. Cerebellar deficit and respiratory impairment: a strong association in multiple sclerosis? Acta Neurol Scand. 2000;101:98-103. (Pubitemid 30051378)
53. Carvalho SR, Alvarenga Filho H, Papais-Alvarenga RM, Chacur FH, Dias RM. Is it useful to perform carbon monoxide diffusion capacity and respiratory muscle function tests in patients with multiple sclerosis without disability? Respirology. 2012;17:869-75.
54. Smeltzer SC, Skurnick JH, Troiano R, Cook SD, Duran W, Lavietes MH. Respiratory function in multiple sclerosis. Utility of clinical assessment of respiratory muscle function. Chest. 1992;101:479-84.
55. Tantucci C, Massucci M, Piperno R, Betti L, Grassi V, Sorbini CA. Control of breathing and respiratory muscle strength in patients with multiple sclerosis. Chest. 1994;105:1163-70. (Pubitemid 24112809)
56. Caminero A, Bartolomé M. Sleep disturbances in multiple sclerosis. J Neurol Sci. 2011;309:86-91.
57. Ferini-Strambi L, Filippi M, Martinelli V, Oldani A, Rovaris M, Zucconi M, Comi G, Smirne S. Nocturnal sleep study in multiple sclerosis: correlations with clinical and brain magnetic resonance imaging findings. J Neurol Sci. 1994;125:194-7. (Pubitemid 24275318)
58. Brass SD, Duquette P, Proulx-Therrien J, Auerbach S. Sleep disorders in patients with multiple sclerosis. Sleep Med Rev. 2010;14:121-9.
59. De Hert S, Imberger G, Carlisle J, Diemunsch P, Fritsch G, Moppett I, Solca M, Staender S, Wappler F, Smith A, Task Force on Preoperative Evaluation of the Adult Noncardiac Surgery Patient of the European Society of Anaesthesiology. Preoperative evaluation of the adult patient undergoing noncardiac surgery: guidelines from the European Society of Anaesthesiology. Eur J Anaesthesiol. 2011;28:684-722.
60. Culley DJ, Crosby G. Neurologic disease and anesthesia. In: Cotrell JE, Smith S, editors. Anesthesia and neurosurgery. St. Louis: Mosby; 2001. p. 617-8.
61. Lensch E, Jost WH. Autonomic disorders in multiple sclerosis. Autoimmune Dis. 2011;2011:803841.
62. Flachenecker P, Reiners K, Krauser M, Wolf A, Toyka KV. Autonomic dysfunction in multiple sclerosis is related to disease activity and progression of disability. Mult Scler. 2001;7:327-34. (Pubitemid 33026258)
63. Merico A, Piccione F, Levedianos G, Vescovo G, Tonin P. Autonomic and cardiac testing in multiple sclerosis patients complaining of fatigue during rehabilitative treatment. Basic Appl Myol. 2005;15:87-92.
64. Uhthoff W. Untersuchungen uber die bei der multiplen Herdsklerose vorkommenden Augenstorungen. Arch Psychiatr Nervenkr. 1889;20:55.
65. Martinez-Rodriguez JE, Munteis E, Roquer J. Periodic hyperthermia and abnormal circadian temperature rhythm in a patient with multiple sclerosis. Mult Scler. 2006;12:515-7. (Pubitemid 44132595)
66. Yamashita K, Yokoyama T, Tokai H, Imazu Y, Lee M, Manabe M. Anesthetic management for a patient with multiple sclerosis at exacerbation stage under general anesthesia. Masui. 2003;52:521-3. (Pubitemid 36702263)
67. Inoue S, Furuya H. Sevoflurane is safe for anesthetic management in patients with multiple sclerosis. Acta Anaesthesiol Taiwan. 2006;44:187-9. (Pubitemid 44463177)
68. Kono Y, Ueda N, Kano T. Anesthetic management for a patient with multiple sclerosis. Masui. 2005;54:906-8. (Pubitemid 41191849)
69. Takano E, Serita R, Hotta M, Yumura J, Ouchi T, Koitabashi T. An anesthetic case of a patient with multiple sclerosis and supranuclear palsy. Masui. 2010;59:906-10.
70. Lee KH, Park JS, Lee SI, Kim JY, Kim KT, Choi WJ, Kim JW. Anesthetic management of the emergency laparotomy for a patient with multiple sclerosis. A case report. Korean J Anesthesiol. 2010;59:359-62.
71. Kulkarni LM, Sanikop C, Shilpa H, Vinayan A. Anaesthetic management in a patient with multiple sclerosis. Indian J Anaesth. 2011;55:64-7.
72. Briggs ED, Kirsch JR. Anesthetic implications of neuromuscular disease. J Anesth. 2003;17:177-85. (Pubitemid 37258726)
73. Sahin L, Korkmaz HF, Sahin M, Aydin T, Toker S, Gulcan E. Desflurane anaesthesia in a patient with multiple sclerosis in total hip replacement. Arch Med Sci. 2010;6:984-6.
74. Ceyhan A, Uyar ET, Gencay IY, Gunal SE. Anesthesia in multiple sclerosis and obstructive sleep apnea: case report and literature review. J Res Med Sci. 2011;16:828-35.
75. Honarmand A, Safavi MR. Comparison of prophylactic use of midazolam, ketamine, and ketamine plus midazolam for prevention of shivering during regional anaesthesia: a randomized double-blind placebo controlled trial. Br J Anaesth. 2008;101:557-62.
76. Anand S, Bhatia A, Rajkumar, Sapra H, Gupta V, Mehta Y. Dexmedetomidine for monitored anesthesia care in patients undergoing liberation procedure for multiple sclerosis: an observational study. Saudi J Anaesth 2012;6:358-362.
77. Martyn JA, White DA, Gronert GA, Jaffe RS, Ward JM. Up-and-down regulation of skeletal muscle acetylcholine receptors. Effects on neuromuscular blockers. Anesthesiology. 1992;76:822-43.
78. Kyttä J, Rosenberg PH. Anaesthesia for patients with multiple sclerosis. Ann Chir Gynaecol. 1984;73:299-303. (Pubitemid 15178403)
79. Cooperman LH. Succinylcholine-induced hyperkalemia in neuromuscular disease. JAMA. 1970;213:1867-71.
80. Levine M, Brown DF. Succinylcholine-induced hyperkalemia in a patient with multiple sclerosis. J Emerg Med. 2012;43:279-82.
81. Jaffe RS, Gronert GA, Fleming NW, Antognini JF. Neuromuscular disorders and muscle relaxants. In: Cucchiara RF, Black S, Michenfelder JD, editors. Clinical neuroanesthesia. 2nd ed. Edinburgh: Churchill Livingstone; 1998. p. 456-7.
82. Zhou J, Allen PD, Pessah IN, Naguib M. Neuromuscular disorders and malignant hyperthermia. In: Miller RD, editor. Miller's anesthesia. 7th ed. Edinburgh: Churchill Livingstone; 2009. p. 1172.
83. Schneider KM. AANA journal course: update for nurse anesthetists: an overview of multiple sclerosis and implications for anesthesia. AANA J. 2005;73:217-24. (Pubitemid 40807622)
84. Brett RS, Schmidt JH, Gage JS, Schartel SA, Poppers PJ. Measurement of acetylcholine receptor concentration in skeletal muscle from a patient with multiple sclerosis and resistance to atracurium. Anesthesiology. 1987;66:837-9. (Pubitemid 17088991)
85. Venkatraghavan L, Manninen P. Anesthesia for deep brain stimulation. Curr Opin Anaesthesiol. 2011;24:495-9.
86. Venkatraghavan L, Luciano M, Manninen P. Review article: anesthetic management of patients undergoing deep brain stimulator insertion. Anesth Analg. 2010;110:1138-45.
87. Leiknes KA, Jarosh von Schweder L, Høie B. Contemporary use and practice of electroconvulsive therapy worldwide. Brain Behav 2012;2:283-344.
88. Fitzsimons MG, Welch CA, Haspel KL, Gorman JM. The safety and efficacy of ECT and anesthesia in the setting of multiple sclerosis. J Psychiatr Pract. 2007;13:195-8.
89. Ding Z, White PF. Anesthesia for electroconvulsive therapy. Anesth Analg. 2002;94:1351-64. (Pubitemid 34441865)
90. Szuba MP, Guze BH, Baxter LR. Electroconvulsive therapy increases circadian amplitude and lowers core body temperature in depressed subjects. Biol Psychiatry. 1997;42:1130-7. (Pubitemid 28049925)
91. Weber F, Rüdel R, Aulkemeyer P, Brinkmeier H. The endogenous pentapeptide QYNAD induces acute conduction block in the isolated rat sciatic nerve. Neurosci Lett. 2002;317:33-6. (Pubitemid 34066511)
92. Brinkmeier H, Aulkemeyer P, Wollinsky KH, Rüdel R. An endogenous pentapeptide acting as a sodium channel blocker in inflammatory autoimmune disorders of the central nervous system. Nat Med. 2000;6:808-11. (Pubitemid 30469431)
93. Bouchard P, Caillet JB, Monnet F, Banssillon V. Spinal anesthesia and multiple sclerosis. Ann Fr Anesth Reanim. 1984;3:194-8.
94. Hebl JR, Horlocker TT, Schroeder DR. Neuraxial anesthesia and analgesia in patients with preexisting central nervous system disorders. Anesth Analg. 2006;103:223-8. (Pubitemid 44036063)
95. Warren TM, Datta S, Ostheimer GW. Lumbar epidural anesthesia in a patient with multiple sclerosis. Anesth Analg. 1982;61:1022-3. (Pubitemid 13224432)
96. Confavreux C, Hutchinson M, Hours MM, Cortinovis-Tourniaire P, Moreau T. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N Engl J Med. 1998;339:285-91. (Pubitemid 28366416)
97. Vukusic S, Confavreux C. Multiple sclerosis and pregnancy. Rev Neurol. 2006;162:299-309.
98. Nelson LM, Franklin GM, Jones MC. Risk of multiple sclerosis exacerbation during pregnancy and breast-feeding. JAMA. 1988;259:3441-3.
99. Dalmas AF, Texier C, Ducloy-Bouthors AS, Krivosic-Horber R. Obstetrical analgesia and anaesthesia in multiple sclerosis. Ann Fr Anesth Reanim. 2003;22:861-4. (Pubitemid 37516850)
100. Bader AM, Hunt CO, Datta S, Naulty JS, Ostheimer GW. Anesthesia for the obstetric patient with multiple sclerosis. J Clin Anesth. 1988;1:21-4.
101. Lirk P, Birmingham B, Hogan Q. Regional anesthesia in patients with preexisting neuropathy. Int Anesthesiol Clin. 2011;49:144-65.
102. Vercauteren M, Heytens L. Anaesthetic considerations for patients with a pre-existing neurological deficit: are neuraxial techniques safe? Acta Anaesthesiol Scand. 2007;51:831-8. (Pubitemid 47062988)
103. Dorotta IR, Schubert A. Multiple sclerosis and anesthetic implications. Curr Opin Anaesthesiol. 2002;15:365-70. (Pubitemid 34596918)
104. D'hooghe MB, Nagels G, Bissay V, De Keyser J. Modifiable factors influencing relapses and disability in multiple sclerosis. Mult Scler. 2010;16:773-85.
105. Wang A, Sinatra RS. Epidural anesthesia for cesarean section in a patient with von Hippel-Lindau disease and multiple sclerosis. Anesth Analg. 1999;88:1083-4. (Pubitemid 29211544)
106. Perlas A, Chan VW. Neuraxial anesthesia and multiple sclerosis. Can J Anaesth. 2005;52:454-8. (Pubitemid 40883303)
107. Levesque P, Marsepoil T, Ho P, Venutolo F, Lesouef JM. Multiple sclerosis disclosed by spinal anesthesia. Ann Fr Anesth Reanim. 1988;7:68-70.
108. Rabadán Díaz JV, López Moreno JA, Soria Quiles A, Del Pino Moreno AL. Neurological deficit during recovery from cesarean section under spinal anesthesia after the appearance of undiagnosed multiple sclerosis. Rev Esp Anestesiol Reanim 2006;53:673-674
109. Sakurai M, Kanazawa I. Positive symptoms in multiple sclerosis: their treatment with sodium channel blockers, lidocaine and mexiletine. J Neurol Sci. 1999;162:162-8. (Pubitemid 29125247)
110. Berger JM, Ontell R. Intrathecal morphine in conjunction with a combined spinal and general anesthetic in a patient with multiple sclerosis. Anesthesiology. 1987;66:400-2. (Pubitemid 17095271)
111. Martucci G, Di Lorenzo A, Polito F, Acampa L. A 12-month follow-up for neurological complication after subarachnoid anesthesia in a parturient affected by multiple sclerosis. Eur Rev Med Pharmacol Sci. 2011;15:458-60.
112. Alvarez JI, Cayrol R, Prat A. Disruption of central nervous system barriers in multiple sclerosis. Biochim Biophys Acta. 2011;1812:252-64.
113. Drake E, Drake M, Bird J, Russell R. Obstetric regional blocks for women with multiple sclerosis: a survey of UK experience. Int J Obstet Anesth. 2006;15:115-23.
114. Sakurai M, Mannen T, Kanazawa I, Tanabe H. Lidocaine unmasks silent demyelinative lesions in multiple sclerosis. Neurology. 1992;42:2088-93.
115. Koeva V, Bar-Or A, Gendron D, Backman SB. Epidural blood patch in a patient with multiple sclerosis: is it safe? Can J Anaesth. 2013;60:479-83.
116. Dawson JW. The histology of disseminated sclerosis. Trans R Soc Edinb. 1916;50:517-725.
117. Boerio D, Creange A, Hogrel JY, Lefaucheur JP. Alteration of motor nerve recovery cycle in multiple sclerosis. Clin Neurophysiol. 2007;118:1753-8. (Pubitemid 47031698)
118. Antonini G, Millefiorini E, Borsellino G, Morino S, Rasura M, Pozzilli C. Subclinical peripheral nervous system involvement in multiple sclerosis. Muscle Nerve. 1995;18:1216-7.
119. Poser CM. The peripheral nervous system in multiple sclerosis. A review and pathogenetic hypothesis. J Neurol Sci. 1987;79:83-90. (Pubitemid 17069979)
120. Ng K, Howells J, Pollard JD, Burke D. Up-regulation of slow K(+) channels in peripheral motor axons: a transcriptional channelopathy in multiple sclerosis. Brain. 2008;131:3062-71.
121. Ng K, Howells J, Pollard JD, Burke D. Different mechanisms underlying changes in excitability of peripheral nerve sensory and motor axons in multiple sclerosis. Muscle Nerve. 2013;47:53-60.
122. Misawa S, Kuwabara S, Mori M, Hayakawa S, Sawai S, Hattori T. Peripheral nerve demyelination in multiple sclerosis. Clin Neurophysiol. 2008;119:1829-33.
123. Vogt J, Paul F, Aktas O, Müller-Wielsch K, Dörr J, Dörr S, Bharathi BS, Glumm R, Schmitz C, Steinbusch H, Raine CS, Tsokos M, Nitsch R, Zipp F. Lower motor neuron loss in multiple sclerosis and experimental autoimmune encephalomyelitis. Ann Neurol. 2009;66:310-22.
124. Gartzen K, Katzarava Z, Diener HC, Putzki N. Peripheral nervous system involvement in multiple sclerosis. Eur J Neurol. 2011;18:789-91.
125. Koff MD, Cohen JA, McIntyre JJ, Carr CF, Sites BD. Severe brachial plexopathy after an ultrasound-guided single-injection nerve block for total shoulder arthroplasty in a patient with multiple sclerosis. Anesthesiology. 2008;108:325-8. (Pubitemid 351156743)
126. Sia S. Nerve blocks, ultrasounds, and multiple sclerosis. Anesthesiology. 2008;109:751-2.
127. Borgeat A, Aguirre J, Neudörfer C, Jutzi H. Severe brachial plexopathy after an ultrasound-guided single-injection nerve block for total shoulder arthroplasty in a patient with multiple sclerosis: what is the likely cause of this complication? Anesthesiology. 2008;109:750-1.
128. Finucane BT, Terblanche OC. Prolonged duration of anesthesia in a patient with multiple sclerosis following paravertebral block. Can J Anaesth. 2005;52:493-7. (Pubitemid 40883310)
129. Ingrosso M, Cirillo V, Papasso A, Merolla V, Cecere F. Femoral and sciatic nerves block (BiBlock) in orthopedic traumatologic lower limbs surgery in patients with multiple sclerosis. Minerva Anestesiol. 2005;71:223-6. (Pubitemid 41557142)
130. Hebl JR. Ultrasound-guided regional anesthesia and the prevention of neurologic injury: fact or fiction? Anesthesiology. 2008;108:186-8. (Pubitemid 351156727)